Clearside BioMedical Inc (CLSD)

[BioSpecialist]

HOT stock here trading significantly below cash balance , FDA acceptance expected within days with potential FDA decision in Q3 this year . Stock has very strong insider and institutional ownership .This stock is a potential 10 bagger potential play because of its super low valuation .


Market Cap $39 Million
Cash $65 Million
Price 1.23

Shares Out 32 million


Clearside Biomedical submits NDA for XIPERE in macular edema associated with uveitis
http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis


Uveitis is a set of ocular inflammatory conditions and is one of the leading causes of vision loss, affecting about 350,000 patients in the U.S. and more than one million worldwide.

If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024.


Largest shareholders :

Wellington Management Co. LLP 4 397 523
Hatteras Venture Partners 3 466 394
Bradford T. Whitmore, MBA 3 200 000
BlackRock Fund Advisors 1 764 105
The Vanguard Group, Inc. 1 198 301
Sphera Funds Management Ltd. 1 154 690
Rock Springs Capital Management LP 975 000
Millennium Management LLC 899 428
AWM Investment Co., Inc. 875 126
Sofinnova Ventures, Inc. 606 914